Wells Fargo & Company Reata Pharmaceuticals Inc Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RETA
# of Institutions
5Shares Held
62.7KCall Options Held
0Put Options Held
0-
Tekla Capital Management LLC34.3KShares$00.14% of portfolio
-
Eaton Vance Management Boston, MA15.6KShares$00.0% of portfolio
-
Stonnington Group, LLC10.1KShares$00.24% of portfolio
-
Pictet Asset Management Sa Geneva 73, V82.65KShares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,73Shares$00.0% of portfolio
About REATA PHARMACEUTICALS INC
- Ticker RETA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,583,200
- Description
- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...